Food, cosmetic, agrochemical, and pharmaceutical giants invest billions of dollars each year to enhance the value and efficacy of their products. While large corporations, like Ashland, BASF, DSM, and Dow dominate upstream development, maintaining their competitive edge will depend on wisely partnering with innovative startups along the value chain. In its latest report, Lux Research assesses technology developers to help users stay ahead of the curve.
The report, titled “Targeting Emerging Delivery Technologies across the Value Chain: From Chemicals and Materials Suppliers to End-Products and Applications,” applies the Lux Innovation Grid framework to evaluate developers of targeted delivery technologies including advanced materials, encapsulation technologies, biological and chemical targeting platforms, delivery devices, and processing technologies.
“Novel technologies are really the backbone of targeted delivery: Continued innovation strengthens products all along the value chain,” said Chananit Sintuu, a researcher for Lux Research, and the report’s lead author. “Also, since a particular targeted delivery technology can offer value across different industries, materials developers have plenty of opportunities to partner up and enter new markets.”
The Lux Innovation Grid builds on information gathered in more than 250 executive interviews to assess the technical and business merits of over 100 companies, and also illustrates how companies compare within their respective technology areas. Evaluating companies using this tool, the report finds that:
- Upstream providers strengthen targeted delivery’s backbone with expertise and innovation. Large chemicals and materials companies will capitalize on their substantial expertise and knowledge by collaborating with emerging delivery developers. This trend is already evident in chemicals supplier BASF’s partnership with OrganoBalance to develop a probiotic delivery system to promote oral health. Likewise, Dow Corning teamed up with Elevance to develop a line of soy-based actives for incorporation into face creams and lotions.
- Targeted delivery technologies will migrate from medical to other applications. Delivery technologies initially aimed at medical and pharmaceutical applications are quickly adapting to address opportunities in other verticals, such as food and beverage markets (where they may lower sodium without the loss of flavor) and cosmetics (where they can enhance anti-wrinkle creams without the use of harsh chemicals).
- Health care will continue to dominate delivery technology applications. The health care sector will never lose its spot at the top of the food chain. However, in the wake of looming patent expiries and diminishing drug product pipelines, large pharmaceutical companies will look abroad to expand and diversify product portfolios with new delivery technologies. Sanofi-aventis, for example, recently acquired a smaller China-based pharmaceutical company and established a consumer health care venture in China. Expect many others to follow.
“Targeting Emerging Delivery Technologies across the Value Chain: From Chemicals and Materials Suppliers to End-Products and Applications,” is part of the Lux Targeted Delivery Intelligence service. Clients subscribing to this service receive ongoing research on market and technology trends, continuous technology scouting reports and proprietary data points in the bi-weekly Lux Research Targeted Delivery Journal, and on-demand inquiry with Lux Research analysts.
Lux Research provides strategic advice and on-going intelligence for emerging technologies. Leaders in business, finance and government rely on us to help them make informed strategic decisions. Through our unique research approach focused on primary research and our extensive global network, we deliver insight, connections and competitive advantage to our clients. Visit http://www.luxresearchinc.com for more information.